Migrants sometimes find themselves unable to remain in a host or transit country — due to lack of legal status, detention, or ...

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

Sleep deprivation has quietly become one of the most pervasive public health issues of the modern era, impacting ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

Targeted modulation of certain intracellular signaling proteins could represent an exciting new approach to drug development. In a recently published review, a research team led by MedUni Vienna ...

Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...

The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...

The FDA’s Breakthrough Devices Program is designed to accelerate development and review of devices that offer meaningful advances in care for serious or life-threatening conditions. With more than ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...